Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A Study Evaluating the Antipyretic Efficacy and Safety of an Acetaminophen/Naproxen Sodium Fixed Combination in Subjects With Endotoxin-Induced Fever

17. listopadu 2026 aktualizováno: Kenvue Brands LLC

A Randomized, Single-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Antipyretic Efficacy and Safety of an Acetaminophen/Naproxen Sodium Fixed Combination in Subjects With Endotoxin-Induced Fever

To evaluate the antipyretic efficacy of a single dose of a fixed combination of acetaminophen/naproxen sodium, compared with placebo.

Přehled studie

Detailní popis

This will be a randomized, single-dose, double-blind, placebo-controlled, parallel-group study to evaluate the antipyretic efficacy and safety of a fixed-dose combination (FDC) of acetaminophen/naproxen sodium in adult subjects with endotoxin-induced fever, compared to placebo.

The study will be conducted in two study phases (Phase A and Phase B), with the intent of Phase A being for endotoxin dose evaluation and the intent of Phase B being to evaluate the investigational product (IP)/placebo.

Subjects enrolled in Phase A will not be included in Phase B, nor will data from these subjects be included in the statistical analysis. Phase A will be completed prior to starting Phase B. Data from Phase A will be reviewed by the Phase A Data Review Team to determine if a satisfactory endotoxin dosing regimen has been achieved. Once a satisfactory dosing regimen is determined, separate subjects will be enrolled in Phase B. Once the endotoxin induced qualifying fever (temperature ≥38.1°C) is established, eligible subjects will be randomized in a 1:1 allocation to receive a single dose of either the IP or the placebo

Typ studie

Intervenční

Zápis (Odhadovaný)

292

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Tennessee
      • Knoxville, Tennessee, Spojené státy, 37920
        • Nábor
        • AMR Clinical - Knoxville Tennessee
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 55 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Mužský

Popis

Inclusion Criteria

Subjects must meet all of the following inclusion criteria in Sections A and B to be eligible for enrollment into the study:

A) Assessed at Screening Visit (Visit 1):

  1. Has a body mass index (BMI) of 17.5 to 37.0 (inclusive) for subjects who are 18 to 40 years old or a BMI of 17.5 to 35.0 (inclusive) for subjects who are 41 to 55 years old.
  2. Healthy, defined as having no clinically relevant abnormalities or medical conditions identified by a detailed medical history; full physical examination; blood pressure, respiratory rate, and heart rate measurements; 12-lead ECG; and clinical laboratory tests conducted at Visit 1.
  3. Has abstained from all food and drink except water at least 4 hours prior to the clinical laboratory tests at Visit 1.
  4. Has a negative QuantiFERON-TB Gold Plus tuberculosis, hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) test based on clinical laboratory tests at Visit 1.
  5. Has a negative urine drug screening test and a negative breath alcohol test conducted at Visit 1.
  6. Has adequate veins, as determined by visual inspection at Visit 1, for IV catheter insertion.
  7. Is able to comprehend the requirements of the study (based upon clinical site personnel's assessment) and is willing and able to comply with scheduled visits, procedures, and subject responsibilities specified within the informed consent form (ICF).
  8. Has provided written informed consent before participating in any study specific procedures.
  9. Agrees to follow contraception requirements (as defined in the protocol/ICF) for the duration of the study and for at least 30 days after study completion.
  10. Is a non-tobacco/nicotine user or previous user who completely stopped smoking/using any form of tobacco or nicotine-containing product at least 6 months before Visit 1.

B) Assessed at Day 0 and Day 1 (of Visit 2):

  1. Healthy, defined as having no clinically relevant abnormalities or medical conditions identified by a detailed medical history; full physical examination conducted on Day 0 (and symptoms-driven physical exam on Day 1, if applicable); blood pressure, respiratory rate, and heart rate measurements (conducted on Day 0 and Day 1); 12-lead ECG (conducted on Day 1), and clinical laboratory tests (conducted on Day 0).
  2. Has abstained from all food and drink except water at least 4 hours prior to the clinical laboratory tests on Day 0.
  3. Has a negative* urine drug screening test and a negative breath alcohol test conducted on Day 0 (*including a negative result for THC. A positive urine drug screening test for medications that have been prescribed to the subject are acceptable).
  4. Has adequate veins, as determined by visual inspection on Day 0, for IV catheter insertion.
  5. Has an oral temperature between 36.37 °C and 37.21 °C as measured on Day 0 and Day 1. If the subject's oral temperature is not between 36.37 °C and 37.21 °C after a single reading, then 2 additional oral temperature readings will be obtained within a 30-minute period. The average of these 3 consecutive temperature readings must be between 36.37 °C and 37.21 °C, with the highest value within 0.1 °C of the lowest temperature value.
  6. Agrees to follow contraception requirements (as defined in the protocol/ICF) for the duration of the study and for at least 30 days after study completion.

C) Assessed Once Qualifying Fever Established (Randomization Criteria; Phase B Only) Subjects must meet all of the following criteria following endotoxin administration in order to be randomized during Phase B. Subjects who do not meet these criteria will not be randomized.

  1. Has not experienced an allergic reaction or exaggerated systemic response to administration of endotoxin, as determined by the PI or medically qualified designee.
  2. Has not required medical management of an AE that includes an antipyretic treatment.
  3. Has developed an oral temperature of at least 38.1 ºC after endotoxin dosed per study guidelines.

Exclusion Criteria (to be assessed at Visit 1, Day 0 of Visit 2, and Day 1 of Visit 2).

Subjects must not meet any of the following exclusion criteria to be eligible for enrollment into the study

  1. Has a pregnant or nursing partner or a partner who is currently trying to become pregnant.
  2. Is self-reported to be unable to swallow whole large tablets or capsules.
  3. Has participated in any interventional clinical studies within 30 days before Visit 1.
  4. Is related to the persons involved directly or indirectly with the conduct of this study (PI, Sub-Investigator(s), study coordinators, other site personnel, employees/contractors of Kenvue or its subsidiaries, employees of IQVIA) at Visit 1.
  5. Has a known allergy or hypersensitivity to acetaminophen, naproxen, naproxen sodium, ibuprofen, other nonsteroidal anti-inflammatory drugs (NSAIDs) (including acetylsalicylic acid or other salicylates), any of the inactive ingredients in the products, ondansetron, or the endotoxin used in the study.
  6. Has a history of chronic tranquilizer use, heavy drinking, or substance abuse, as judged by the PI or designee, in the last five years.
  7. To be assessed at Day 0: Has consumed alcohol within 48 hours prior to Day 0.
  8. To be assessed at Day 0: Has consumed caffeine or other methylxanthine containing products (e.g., chocolate bars or chocolate beverages, coffee, tea, cola, or caffeinated energy drinks) within 24 hours prior to Day 0.
  9. To be assessed at Day 0: Has experienced cold/flu symptoms (i.e., runny nose, cough, pain, and/or fever) within 2 weeks prior to Day 0.
  10. To be assessed at Day 0: Has used prescription or nonprescription drugs within 5 half-lives prior to Day 0.
  11. To be assessed at Day 0: Has used any drug that may impact gastric motility, such as glucagon-like peptide-1 (GLP-1) medication, within 35 days prior to Day 0.
  12. To be assessed at Day 0: Has used vitamins or dietary/herbal supplements within 7 days prior to Day 0.
  13. Routinely uses oral analgesics ≥ 5 times per week.
  14. Has any disease or condition that may cause abnormal alterations in body temperature.
  15. Has a clotting/bleeding disorder and is at risk of excessive bleeding.
  16. Has evidence or history of a clinically significant laboratory abnormality or hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, immunologic, or allergic disease (excluding untreated, asymptomatic, seasonal allergies at the time of dosing) within the last 5 years that, in the PI's or medically qualified designee's opinion, may jeopardize the subject's safety or well-being or the integrity of the study.
  17. Has any clinically significant gastrointestinal disorder/disease/condition or is taking medication for any such disorder/disease/condition that, per the PI's or medically qualified designee's judgement, could affect the absorption, metabolism, or excretion of the study medication.
  18. Has a history of recurrent, acute, or chronic infections of any type or any findings suggestive of occult infection, such as tuberculosis, sinusitis, urinary tract infection, respiratory tract or dental (abscess) infection, etc. Also excluded are subjects with frequent (more than 3 outbreaks per year), recurrent oral or genital herpes, recurrent herpes zoster, or any infection otherwise judged by the PI or medically qualified designee to have the potential for exacerbation by participation in the study.
  19. Heart rate < 50 bpm or is deemed to be at high risk of syncope and/or hypotension per the clinical judgment of the PI or medically qualified designee at Visit 1, on Day 0, or on Day 1.
  20. Supine blood pressure <90 or >140 mmHg (systolic) or <50 or >90 mmHg (diastolic), following at least 5 minutes of supine rest, as assessed at Visit 1, on Day 0, or on Day 1.
  21. Supine 12-lead ECG demonstrating QTcF >450 msec or a QRS interval >120 msec at Visit 1 or on Day 1 prior to endotoxinadministration.
  22. Other severe, acute or chronic medical or psychiatric condition(s) or laboratory abnormality(ies) that may increase the risk associated with study participation or ISM administration or may interfere with the interpretation of study results.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Acetaminophen 650 mg/Naproxen Sodium 220 mg

Acetaminophen 650 mg/Naproxen Sodium 220 mg (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg).

The IP is to be taken as a single dose (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg) orally with 180 mL of room temperature water.

Komparátor placeba: Placebo

Placebo (administered as two tablets of placebo).

The placebo is to be taken as a single dose (administered as two tablets of placebo) orally with 180 mL of room temperature water.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 8 hours (WSTD 0-8)
Časové okno: Baseline (0 hour) up to 8 hours

WSTD 0-8 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110,120,150,180,210,240,270,300,330,360,390,420,450, and 480 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 8 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours).

Baseline (0 hour) up to 8 hours
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 12 hours (WSTD 0-12)
Časové okno: Baseline (0 hour) up to 12 hours

WSTD 0-12 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80,90,100,110,120,150,180,210,240,270,300,330,360,390,420,450, 480,510,540,570,600,630,660,690,and 720 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 12 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5 , and 12 hours).

Baseline (0 hour) up to 12 hours

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 6 hours (WSTD 0-6)
Časové okno: Baseline (0 hour) up to 6 hours

WSTD 0-6 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110,120,150,180,210,240,270,300,330, and 360 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 6 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours).

Baseline (0 hour) up to 6 hours
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 10 hours (WSTD 0-10)
Časové okno: Baseline (0 hour) up to 10 hours

WSTD 0-10 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80,90,100,110,120,150,180,210,240,270,300,330,360,390,420,450, 480,510,540,570, and 600 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 10 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10 hours).

Baseline (0 hour) up to 10 hours
Subject Global Evaluation Questionnaire
Časové okno: Visit 2 - 12 hours prior to first use of rescue medication, or at time of early discontinuation (whichever occurs first).

Participants will be asked to evaluate the performance of the investigational study material (ISM) using a 5-point Likert scale : 0= poor , 1=fair , 2=good , 3=very good , 4=excellent

Visit 2 - 12 hours prior to first use of rescue medication, or at time of early discontinuation (whichever occurs first).
Time to first use of rescue medication
Časové okno: Baseline (0 hour) to 12 hours

Time to rescue medication (other than study treatment) was defined as time from first dosing of study medication to the time a participant first takes a rescue medication, or to the end of the study time for participants that do not take any rescue medication prior to the end of the study. The rescue medication was defined as medication received for the treatment of fever during the time period from the administration of study medication to the time of end of the study.

Baseline (0 hour) to 12 hours
Proportion of subjects using rescue medication from 0 to 12 hours
Časové okno: Baseline (0 hour) to 12 hours
Baseline (0 hour) to 12 hours

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Ředitel studie: Tobore Tobore, Kenvue Brands LLC

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

20. října 2026

Primární dokončení (Odhadovaný)

29. října 2027

Dokončení studie (Odhadovaný)

29. října 2027

Termíny zápisu do studia

První předloženo

15. října 2026

První předloženo, které splnilo kritéria kontroly kvality

17. listopadu 2026

První zveřejněno (Aktuální)

19. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

19. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. listopadu 2026

Naposledy ověřeno

11. listopadu 2026

Více informací

Termíny související s touto studií

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit